Item 2.02. Results of Operations and Financial Condition.

On January 26, 2021, VYNE Therapeutics Inc. (the "Company") provided the following update on its financial condition:





  · The Company's preliminary estimate of cash, cash equivalents, restricted cash
    and investments is approximately $59.0 million as of December 31, 2020 and its
    preliminary estimate of total revenues for the quarter ended December 31, 2020
    is in the range of $4.0 million to $4.5 million.




  · The Company sold 15,812,050 shares of common stock, par value $0.0001 per
    share, from October 1, 2020 through January 25, 2021 pursuant to the Sales
    Agreement, dated February 1, 2019, by and between the Company and Cantor
    Fitzgerald & Co. in an "at-the-market" offering. The Sales Agreement was
    terminated on January 25, 2021.

The preliminary financial information has been prepared by, and is the responsibility of, Company management. No independent registered public accounting firm, including Kesselman & Kesselman, Certified Public Accountants (lsr.), a member firm of PricewaterhouseCoopers International Limited, has audited, reviewed, compiled or applied agreed-upon procedures with respect to the preliminary financial information. Accordingly, no independent registered public accounting firm expresses an opinion or any other form of assurance with respect thereto. These estimates were prepared by Company management, based upon a number of assumptions, and could change as a result of further review. In particular, the preparation of the annual report on Form 10-K for the fiscal year ended December 31, 2020 could result in changes to this preliminary financial information, and such changes may be material. Additional items that would require material adjustments to the preliminary financial information may be identified. Estimates of results are inherently uncertain and subject to change, and the Company undertakes no obligation to update this information.

The information in this Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

© Edgar Online, source Glimpses